MA39088A1 - Compositions et procédés pour moduler des récepteurs farnesoïde x - Google Patents

Compositions et procédés pour moduler des récepteurs farnesoïde x

Info

Publication number
MA39088A1
MA39088A1 MA39088A MA39088A MA39088A1 MA 39088 A1 MA39088 A1 MA 39088A1 MA 39088 A MA39088 A MA 39088A MA 39088 A MA39088 A MA 39088A MA 39088 A1 MA39088 A1 MA 39088A1
Authority
MA
Morocco
Prior art keywords
compositions
receptors
methods
farnesoid
modulating farnesoid
Prior art date
Application number
MA39088A
Other languages
English (en)
Other versions
MA39088B1 (fr
Inventor
Valentina Molteni
Donatella Chianelli
Xiaodong Liu
John Nelson
Jason Roland
Paul Rucker
David Tully
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39088(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA39088A1 publication Critical patent/MA39088A1/fr
Publication of MA39088B1 publication Critical patent/MA39088B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des composés de formule i, un stéréoisomère, un énantiomère, un sel pharmaceutiquement acceptable ou un acide aminé conjugué de celui-ci, des variables telles que définies dans la description, et leurs compositions pharmaceutiques, qui sont utiles en tant que modulateurs de l'activité de récepteurs farnesoïde x (fxr).
MA39088A 2013-11-05 2014-11-04 Compositions et procédés pour moduler des récepteurs farnesoïde x MA39088B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05
PCT/US2014/063948 WO2015069666A1 (fr) 2013-11-05 2014-11-04 Compositions et procédés pour moduler des récepteurs farnesoïde x

Publications (2)

Publication Number Publication Date
MA39088A1 true MA39088A1 (fr) 2017-07-31
MA39088B1 MA39088B1 (fr) 2018-06-29

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39088A MA39088B1 (fr) 2013-11-05 2014-11-04 Compositions et procédés pour moduler des récepteurs farnesoïde x

Country Status (42)

Country Link
US (5) US9682939B2 (fr)
EP (1) EP3065738B1 (fr)
JP (1) JP6424231B2 (fr)
KR (1) KR102350357B1 (fr)
CN (1) CN105682656B (fr)
AP (1) AP2016009165A0 (fr)
AR (1) AR098316A1 (fr)
AU (1) AU2014346919B2 (fr)
BR (1) BR112016009630B1 (fr)
CA (1) CA2927705C (fr)
CL (1) CL2016000982A1 (fr)
CR (1) CR20160212A (fr)
CU (1) CU24375B1 (fr)
CY (1) CY1120273T1 (fr)
DK (1) DK3065738T3 (fr)
EA (1) EA030430B1 (fr)
ES (1) ES2670984T3 (fr)
GT (1) GT201600085A (fr)
HR (1) HRP20180817T1 (fr)
HU (1) HUE039155T2 (fr)
IL (1) IL245242B (fr)
JO (1) JO3454B1 (fr)
LT (1) LT3065738T (fr)
MA (1) MA39088B1 (fr)
MX (1) MX364834B (fr)
MY (1) MY175903A (fr)
NO (1) NO3105103T3 (fr)
NZ (1) NZ719078A (fr)
PE (1) PE20160682A1 (fr)
PH (1) PH12016500777B1 (fr)
PL (1) PL3065738T3 (fr)
PT (1) PT3065738T (fr)
RS (1) RS57179B1 (fr)
SG (1) SG11201603026PA (fr)
SI (1) SI3065738T1 (fr)
SV (1) SV2016005192A (fr)
TN (1) TN2016000143A1 (fr)
TR (1) TR201807321T4 (fr)
TW (1) TWI662027B (fr)
UY (1) UY35818A (fr)
WO (1) WO2015069666A1 (fr)
ZA (1) ZA201602555B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (fr) 2016-06-13 2025-09-02 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
JP6915050B2 (ja) * 2016-09-14 2021-08-04 ノバルティス アーゲー Ｆｘｒアゴニストの新規のレジーム
PE20190972A1 (es) * 2016-09-14 2019-07-09 Novartis Ag Combinacion de agonistas de fxr
MX2019003889A (es) * 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
WO2018226155A1 (fr) * 2017-06-05 2018-12-13 National University Of Singapore Composés utiles pour inhiber le facteur 3 en feuille de trèfle humain
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
WO2019092171A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020172075A1 (fr) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021009332A1 (fr) 2019-07-18 2021-01-21 Enyo Pharma Procédé pour diminuer les effets secondaires de l'interféron
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (fr) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 Nouvelle forme cristalline d'un dérivé d'acide benzoïque et son procédé de préparation
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4577206A2 (fr) * 2022-08-26 2025-07-02 Celmatix Inc. Nouveaux modulateurs de fshr et leurs utilisations
WO2026133229A1 (fr) 2024-12-20 2026-06-25 Novartis Ag Inhibiteurs de l'inflammasome nlrp3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
DK2029547T3 (da) * 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
JP2010504032A (ja) * 2006-09-15 2010-02-04 タレス アビオニクス インコーポレイテッド 航空機との間でコンテンツを無線で転送するシステム及び方法
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors

Also Published As

Publication number Publication date
TWI662027B (zh) 2019-06-11
CA2927705C (fr) 2021-09-21
US20210253534A1 (en) 2021-08-19
SV2016005192A (es) 2016-11-21
AU2014346919B2 (en) 2017-02-02
AP2016009165A0 (en) 2016-04-30
TN2016000143A1 (en) 2017-10-06
PH12016500777A1 (en) 2016-05-30
NZ719078A (en) 2018-07-27
KR20160079091A (ko) 2016-07-05
HUE039155T2 (hu) 2018-12-28
NO3105103T3 (fr) 2018-05-12
MY175903A (en) 2020-07-15
CA2927705A1 (fr) 2015-05-14
US11021446B2 (en) 2021-06-01
US10077240B2 (en) 2018-09-18
US20160340317A1 (en) 2016-11-24
CR20160212A (es) 2016-07-22
EA030430B1 (ru) 2018-08-31
EA201690930A1 (ru) 2016-08-31
IL245242A0 (en) 2016-06-30
BR112016009630B1 (pt) 2021-02-09
IL245242B (en) 2019-03-31
JO3454B1 (ar) 2020-07-05
US20200247757A1 (en) 2020-08-06
TW201612163A (en) 2016-04-01
CL2016000982A1 (es) 2016-10-07
US20170275256A1 (en) 2017-09-28
KR102350357B1 (ko) 2022-01-14
SI3065738T1 (en) 2018-06-29
RS57179B1 (sr) 2018-07-31
GT201600085A (es) 2019-07-19
SG11201603026PA (en) 2016-05-30
US9682939B2 (en) 2017-06-20
CU24375B1 (es) 2018-12-05
CN105682656A (zh) 2016-06-15
US20190062283A1 (en) 2019-02-28
AR098316A1 (es) 2016-05-26
CN105682656B (zh) 2019-11-05
PT3065738T (pt) 2018-06-04
CU20160063A7 (es) 2016-09-30
PE20160682A1 (es) 2016-07-23
CY1120273T1 (el) 2019-07-10
US10683271B2 (en) 2020-06-16
ZA201602555B (en) 2017-06-28
PH12016500777B1 (en) 2016-05-30
MA39088B1 (fr) 2018-06-29
MX2016005865A (es) 2016-07-13
JP2016535784A (ja) 2016-11-17
UY35818A (es) 2015-05-29
WO2015069666A1 (fr) 2015-05-14
TR201807321T4 (tr) 2018-06-21
MX364834B (es) 2019-05-08
AU2014346919A1 (en) 2016-05-12
JP6424231B2 (ja) 2018-11-14
LT3065738T (lt) 2018-05-10
BR112016009630A8 (pt) 2020-04-07
PL3065738T3 (pl) 2018-07-31
EP3065738A1 (fr) 2016-09-14
HRP20180817T1 (hr) 2018-06-29
EP3065738B1 (fr) 2018-02-28
DK3065738T3 (en) 2018-06-06
ES2670984T3 (es) 2018-06-04

Similar Documents

Publication Publication Date Title
MA39088B1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
MX387172B (es) Moduladores del receptor x farnesoide.
MY195888A (en) N-Substituted Indole Derivatives As Pge2 Receptor Modulators
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA35716B1 (fr) Formulations pharmaceutiques
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
EP3695830A4 (fr) Utilisation d'une composition comprenant des exosomes dérivés de cellules souches en tant que principe actif pour le renforcement et l'amélioration fonctionnelle de la barrière cutanée
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201992679A1 (ru) N-замещенные индольные производные
MA34805B1 (fr) Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MY210362A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
TR201908151T4 (tr) İzoindolin türevleri.
MX393789B (es) Moduladores de los receptores a3 de adenosina
WO2015138276A3 (fr) Modulateurs du récepteur orphelin lié au récepteur de l'acide rétinoïque et leurs utilisations
WO2015138280A3 (fr) Modulateurs des récepteurs orphelins associés au récepteur de l'acide rétinoïque et leurs utilisations